UBS Maintains a 'Neutral' on Vertex (VRTX); Potential CF Program Advancement
Tweet Send to a FriendGet Alerts VRTX Hot Sheet
Price: $77.48 -2.53%
Rating Summary:
17 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 12
Rating Summary:
17 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 12
Trade VRTX Now!
UBS maintains a 'Neutral' on Vertex (NASDAQ: VRTX) price target raised from $35 to $44.
Analyst, Matthew Roden, said, "Our thoughts: 1) Our prior $35 PT looks more like a downside case scenario, and we see more optionality to the upside as we do not include the pipeline in our valuation; 2) We acknowledge that the cystic fibrosis (CF) franchise could develop into a multi-billion dollar opportunity; 3) However, we continue to not expect significance on FEV1 in the ph2 study of VX-770/809 in CF patients, which would limit near term upside; 4) We see risk of incremental downside if GS-7977 data impress in HCV."
UBS lowers FY12 EPS estimate from $4.44 to $4.21 and FY13 from $5.05 to $4.78.
For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.
Shares of Vertex closed at $40.95 yesterday, with a 52 week range of $26.50-$58.87.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Matthew Roden, said, "Our thoughts: 1) Our prior $35 PT looks more like a downside case scenario, and we see more optionality to the upside as we do not include the pipeline in our valuation; 2) We acknowledge that the cystic fibrosis (CF) franchise could develop into a multi-billion dollar opportunity; 3) However, we continue to not expect significance on FEV1 in the ph2 study of VX-770/809 in CF patients, which would limit near term upside; 4) We see risk of incremental downside if GS-7977 data impress in HCV."
UBS lowers FY12 EPS estimate from $4.44 to $4.21 and FY13 from $5.05 to $4.78.
For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.
Shares of Vertex closed at $40.95 yesterday, with a 52 week range of $26.50-$58.87.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Wedbush Downgrades XenoPort (XNPT) to Neutral
- Best Buy (BBY) May Show Progress on Earnings Front, UBS Remains Neutral
- Needham & Company Lifts Numbers on 3D Systems (DDD) on Offering, RDPG Deal
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
UBS
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
